Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:CDTX NASDAQ:PTCT NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$41.87+1.3%$30.30$16.50▼$43.58$3.60BN/A11,313 shs5,040 shsCDTXCidara Therapeutics$50.96+1.0%$28.84$10.14▼$56.83$1.02B1.14192,861 shs1.25 million shsPTCTPTC Therapeutics$48.74+2.3%$48.11$29.02▼$58.38$3.78B0.5870,066 shs1.42 million shsRAREUltragenyx Pharmaceutical$41.44+5.1%$36.82$27.23▼$60.37$3.73B0.26850,325 shs2.60 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-1.64%+6.05%+45.70%+117.63%+4,134,999,900.00%CDTXCidara Therapeutics+4.45%+2.90%+100.04%+188.78%+328.27%PTCTPTC Therapeutics-0.69%-1.93%-8.59%+11.46%+50.17%RAREUltragenyx Pharmaceutical-0.48%+8.71%+6.05%+16.25%-4.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/ACDTXCidara Therapeutics4.1236 of 5 stars3.62.00.04.63.11.70.0PTCTPTC Therapeutics4.291 of 5 stars4.31.00.04.41.50.81.3RAREUltragenyx Pharmaceutical4.0721 of 5 stars3.51.00.03.82.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/ACDTXCidara Therapeutics 3.11Buy$57.1412.13% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$65.0033.36% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$87.00109.94% UpsideCurrent Analyst Ratings BreakdownLatest CDTX, PTCT, RARE, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$59.006/24/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/24/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$35.00 ➝ $75.006/24/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$50.00 ➝ $68.006/23/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$41.00 ➝ $53.006/23/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $54.006/23/2025CDTXCidara TherapeuticsWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$45.006/20/2025RAREUltragenyx PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.006/18/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$41.006/17/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.006/10/2025CDTXCidara TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M27.15N/AN/A$0.48 per share87.23CDTXCidara Therapeutics$1.27M808.94N/AN/A$14.92 per share3.42PTCTPTC Therapeutics$806.78M4.79N/AN/A($14.24) per share-3.42RAREUltragenyx Pharmaceutical$560.23M6.99N/AN/A$2.76 per share15.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/ACDTXCidara Therapeutics-$169.83M-$29.470.00N/AN/AN/A-73.04%-54.28%8/12/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.516.57N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.880.00N/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)Latest CDTX, PTCT, RARE, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45-$1.66+$3.79-$1.66N/AN/A5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International3.241.261.26CDTXCidara TherapeuticsN/A3.873.87PTCTPTC TherapeuticsN/A3.893.85RAREUltragenyx PharmaceuticalN/A2.402.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ACDTXCidara Therapeutics35.82%PTCTPTC TherapeuticsN/ARAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ACDTXCidara Therapeutics3.89%PTCTPTC Therapeutics5.50%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.12 millionN/AN/ACDTXCidara Therapeutics9020.16 million19.38 millionNo DataPTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableCDTX, PTCT, RARE, and AAPG HeadlinesRecent News About These CompaniesUltragenyx stock plummets after OI drug study continues to final analysis3 hours ago | investing.comUltragenyx and Mereo BioPharma Progress Phase 3 Study of Setrusumab in Pediatric Osteogenesis Imperfecta Patients5 hours ago | quiverquant.comQUltragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis5 hours ago | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by KBC Group NVJuly 8 at 3:37 AM | marketbeat.comWCM Investment Management LLC Has $7.65 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)July 3, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 3, 2025 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 3, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 6.3% - Should You Buy?July 2, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Below 50 Day Moving Average - What's Next?July 1, 2025 | marketbeat.comRARE's GTX-102 Gets FDA's Breakthrough Status for Angelman SyndromeJune 30, 2025 | zacks.comUltragenyx stock rises after FDA grants breakthrough therapy status for Angelman syndrome drugJune 27, 2025 | au.investing.comUltragenyx Gets FDA Designation to Expedite GTX-102 Drug DevelopmentJune 27, 2025 | marketwatch.comUltragenyx Pharmaceutical Inc. Receives FDA Breakthrough Therapy Designation for GTX-102 to Treat Angelman SyndromeJune 27, 2025 | quiverquant.comQUltragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman SyndromeJune 27, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders Sells 2,405 SharesJune 24, 2025 | insidertrades.comFDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding IntentJune 23, 2025 | biospace.comBInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Sells 2,405 Shares of StockJune 23, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. Grants 48,731 Restricted Stock Units to Newly Hired Non-Executive OfficersJune 20, 2025 | quiverquant.comQUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2025 | globenewswire.comGuggenheim Reaffirms Buy Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)June 20, 2025 | marketbeat.comGAMMA Investing LLC Acquires 26,625 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTesla’s Robotaxi Hype Fuels Bullish Price Targets to $500By Sam Quirke | June 30, 2025View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500Why Qualcomm’s Latest Price Target Can't Be IgnoredBy Sam Quirke | June 24, 2025View Why Qualcomm’s Latest Price Target Can't Be IgnoredTesla Stock: Why These 2 Downgrades Are Actually a Buy SignalBy Sam Quirke | June 11, 2025View Tesla Stock: Why These 2 Downgrades Are Actually a Buy SignalBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsBy Nathan Reiff | June 30, 2025View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsTop 5 Undervalued Dividend Stocks With Strong Payout PotentialBy Ryan Hasson | July 7, 2025View Top 5 Undervalued Dividend Stocks With Strong Payout PotentialCDTX, PTCT, RARE, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$41.87 +0.52 (+1.26%) As of 03:59 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Cidara Therapeutics NASDAQ:CDTX$50.96 +0.51 (+1.01%) Closing price 04:00 PM EasternExtended Trading$49.65 -1.31 (-2.57%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.PTC Therapeutics NASDAQ:PTCT$48.74 +1.09 (+2.29%) Closing price 04:00 PM EasternExtended Trading$48.78 +0.04 (+0.09%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Ultragenyx Pharmaceutical NASDAQ:RARE$41.44 +2.02 (+5.12%) Closing price 04:00 PM EasternExtended Trading$30.67 -10.77 (-25.98%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
